Back to top

Image: Bigstock

Pfizer (PFE) Stock Sinks As Market Gains: What You Should Know

Read MoreHide Full Article

In the latest trading session, Pfizer (PFE - Free Report) closed at $52.74, marking a -1.01% move from the previous day. This change lagged the S&P 500's 1.23% gain on the day. At the same time, the Dow added 0.97%, and the tech-heavy Nasdaq gained 0.44%.

Prior to today's trading, shares of the drugmaker had gained 13.51% over the past month. This has outpaced the Medical sector's gain of 4.31% and the S&P 500's gain of 4.69% in that time.

Investors will be hoping for strength from Pfizer as it approaches its next earnings release. The company is expected to report EPS of $1.80, up 93.55% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $28.72 billion, up 96.99% from the year-ago period.

For the full year, our Zacks Consensus Estimates are projecting earnings of $7.20 per share and revenue of $115.85 billion, which would represent changes of +62.9% and +42.17%, respectively, from the prior year.

It is also important to note the recent changes to analyst estimates for Pfizer. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.

Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.

The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 3.28% higher. Pfizer is currently sporting a Zacks Rank of #3 (Hold).

Investors should also note Pfizer's current valuation metrics, including its Forward P/E ratio of 7.4. This represents a discount compared to its industry's average Forward P/E of 12.88.

We can also see that PFE currently has a PEG ratio of 0.78. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. PFE's industry had an average PEG ratio of 2.32 as of yesterday's close.

The Large Cap Pharmaceuticals industry is part of the Medical sector. This group has a Zacks Industry Rank of 157, putting it in the bottom 39% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.


In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


Pfizer Inc. (PFE) - free report >>

Published in